In-vitro efficacy of antibacterials against bacterial isolates from corneal ulcers

Indian Journal of Ophthalmology

Volumn 50, Issue 2, 2002, Pages 109-114

  Jayahar Bharathi, M ^a   Ramakrishnan, R ^a   Vasu, Samala ^a   Meenakshi, R ^a   Palaniappan, R ^b  

^a ARAVIND EYE HOSPITAL   (India)

^b SRI PARAMAKALYANI COLLEGE   (India)

Author keywords

Antibacterial susceptibility; Culture; Microbial keratitis; Microscopy; Scraping

Indexed keywords

ANTIINFECTIVE AGENT; CEFALORIDINE; CEFAZOLIN; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; NORFLOXACIN; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIUM CULTURE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; CORNEA; CORNEA ULCER; CORYNEBACTERIUM; DRUG EFFICACY; ENTEROBACTER; ESCHERICHIA COLI; HAEMOPHILUS; HUMAN; HUMAN TISSUE; KERATITIS; KLEBSIELLA; MEDICAL DECISION MAKING; MICROCOCCUS; MORAXELLA; NEISSERIA; NOCARDIA; PROTEUS; PSEUDOMONAS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; ANTIBIOTIC RESISTANCE; BACTERIUM; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTIBIOTICS; BACTERIA; CORNEA; CORNEAL ULCER; DRUG RESISTANCE, BACTERIAL; HUMAN; MICROBIAL SENSITIVITY TESTS; ANTI-BACTERIAL AGENTS; HUMANS;

EID: 0036019451     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Burd EM, Ogawa GSH, Hyndiuk RA. Bacteria J keratitis and conjunctivitis. In: Smolin G, Thoft RA, editors. The Cornea, Scientific Foundations and Clinical Practice. Boston: Little, Brown & Company; 1994. pp 115-67.
2. Srinivasan M, Gonzales CA, George C, Cevallos V, Mascarenhas JM, Asokan B, et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India. Br J Ophthalmol 1997;81:965-71.
3. Upadhyay MP, Karmacharya PC, Koirala S, Tuladhar NR, Bryan LE, Smolin G, et al. Epidemiologic characheritis, predisposing factors, and etiologic diagnosis of corneal ulceration in Nepal. Am J Ophthalmol 1991;111:92-99.
4. Agarwal V, Biswas J, Madhavan HN, Mangat G, Reddy MK, Saini JS, et al. Current perspectives in Infection. Indian J Ophthalmol 1994;42:171-91.
5. Leopold IH. Update on antibiotics in ocular infections. Am J Ophthalmol 1985;100:134-40.
6. Pinna A, Zanette S, Sotgiu M, et al. Idetification and antibiotic susceptiblity of coagulase-negative Staphylococci isolated in corneal / external infections. Br J Ophthalmol 1999;83:771-3.
7. Srikanth K, Kalavathy CM, Thomas PA, Jesudasan CAN. Susceptiblity of common ocular bacterial pathogens to antibacterial agents. Journal of TNOA 1998;39:49-50.
8. Archer GL, Climo MW. Antimicrobial susceptibilty of coagulase-negative Staphylococci. Antimicrob Agents Chemother 1994;38:2231-7.
9. Mahajan VM. Acute bacterial infections of the eye: their aetiology and treatment. Br J Ophthalmol 1983;67:191-94
10. Jones DB. Early diagnosis and theraphy of bacterial corneal ulcer. Int Ophthalmol Clin 1973;13:1-29
11. Barry AL, Thornsberry C. Susceptibilty test: Diffusion Test Procedures. In: Lennette EH, Balows A, Hausler WJ, Shadomy HJ, editors. Manual of clinical microbiology. Washington, D.C: American Society for Microbiology; 1985. p 978-87.
12. Sharma S, Kunimoto DY, Garg P, Rao GN. Trends in antibiotic resistance of corneal pathogens: Part I. An analysis of commonly used ocular antibiotics. Indian J Ophthalmol 1999;47:95-100.
13. Hughes MS, Bakert AS. Toxicity of ocular antiinfectives. In: Albert DM, Jakobiec FA, editors. Principles and Practice of Ophthalmology. Philadelphia: W.B. Saunders Company; 2000. Vol 1, p 417-68
14. Carpenter G. Chloramphenicol eye-drops and marrow aplasia(letter). Lancet 1975;2:236.
15. Langsten PD, Dunkel EC. Handbook of Ocular Drugs Therapy and Ocular Side Effects of Systemic Drugs. Boston: Little, Brown and Company; 1991. p 22-83.
16. Rosenthal RL, Blackman A. Bone marrow hypoplasia following use of chloramphenicol eye drops. JAMA 1965;191:136-37
17. Abramowicz M. Chloramphenicol ophthalmic formulations. Med Lett Drugs Ther 1980;22:96.
18. Roberts W. Topical use of chloramphenicol in external ocular infections. Am J Ophthalmol 1951;34:1081.
19. Beasley H, Boltralik JJ, Baldwin HA. Chloramphenicol in aqueous humour after topical application. Arch Ophthalmol 1975;93:184-186.
20. Mitsiu Y, Takeshima R, Fujimoto M, Kashyama T. Deposits of mucosubstances on the cornea by topical chloramphenicol: a electron microscopic study. Invest Ophthalmol Vis Sci 1976;15:211.
21. West BQ Devault GA, Clement JC, Williams DM. Aplastic anemia associated with parental chloramphenicol: review of 10 cases, including the second case of possible increased risk with cimetidine. Rev Infect Dis 1988;10:1048-51.
22. Hyndiuk RA, Eiferman RA, Caldwell DR, Rosenwasser GO, Santos CI, Katz HR, et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcer. Opthalmology 1996;103:1854-62.
23. Snyder ME, Hatz HR. Ciprofloaxcin-resistant bacterial keratitis. Am J Ophthalmol 1992;114:336-38.
24. Leibowitz HM. Clinical evaluation of ciprofloxacin 0.3% ophthalmic solution for treatment of bacterial keratitis. Am J Ophthalmol 1991;112:34S-47S.
25. Jones DB. Decision-making in the management of microbial keratitis. Ophthalmology 1981;88:814-20.
26. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol 1995;113:1257-65.
27. Ormerod LD, Heseltine PNR, Alfonso E, Becker MI, Kenyon KR, Baerveldt G, et al. Gentamicin-resistant Pseudomonal infection: Rationale for redefinition of ophthalmic antimicrobial sensitivities. Cornea 1989;8:195-99.